Sunitinib-resistant PDGFR mutants

Stable Identifier
R-HSA-9674401
Type
Pathway
Species
Homo sapiens
ReviewStatus
5/5
Locations in the PathwayBrowser
Expand all
General
SVG | 
PNG
Low
Medium
High
 | PPTX  | SBGN
Sunitinib-resistant PDGFR mutants
Click the image above or here to open this pathway in the Pathway Browser
Sunitinib is a class II TKI that is often used as a second-line treatment in PDGFR- and KIT-driven cancers that develop resistance to imatinib (reviewed in Corless et al, 2011; Klug et al, 2018). Sunintib is approved for the treatment of renal cell carcinoma, GIST and pancreatic tumors. A number of PDGFR mutations exhibit resistance to inhibition by sunitinib (Roskoski, 2007; reviewed in Roskoski, 2018; Klug et al, 2018).
Literature References
PubMed ID Title Journal Year
22089421 Gastrointestinal stromal tumours: origin and molecular oncology

Barnett, CM, Corless, CL, Heinrich, MC

Nat. Rev. Cancer 2011
29408302 The role of small molecule platelet-derived growth factor receptor (PDGFR) inhibitors in the treatment of neoplastic disorders

Roskoski, R

Pharmacol. Res. 2018
29964125 Structural and clinical consequences of activation loop mutations in class III receptor tyrosine kinases

Heinrich, MC, Kent, JD, Klug, LR

Pharmacol. Ther. 2018
17367763 Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor

Roskoski, R

Biochem. Biophys. Res. Commun. 2007
Participants
Events
Participates
as an event of
Disease
Name Identifier Synonyms
cancer DOID:162 malignant tumor, malignant neoplasm, primary cancer
Authored
Rothfels, K  (2020-02-25)
Reviewed
Ip, CKM  (2020-02-06)
Created
Rothfels, K  (2020-01-13)
Cite Us!